OncoSec Medical (NASDAQ:ONCS) has been assigned a $6.00 price objective by HC Wainwright in a research report issued to clients and investors on Friday, January 19th. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 240.91% from the company’s current price.
A number of other analysts have also commented on ONCS. ValuEngine lowered shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Monday, October 2nd. Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of OncoSec Medical in a report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. OncoSec Medical currently has a consensus rating of “Buy” and an average target price of $5.00.
OncoSec Medical (NASDAQ:ONCS) traded up $0.12 on Friday, reaching $1.76. 822,526 shares of the company’s stock were exchanged, compared to its average volume of 993,311. OncoSec Medical has a 12-month low of $0.88 and a 12-month high of $2.95. The firm has a market cap of $70.42, a price-to-earnings ratio of -1.66 and a beta of 3.34.
In other OncoSec Medical news, CEO Daniel J. O’connor bought 16,667 shares of the stock in a transaction on Monday, February 5th. The stock was purchased at an average price of $1.50 per share, with a total value of $25,000.50. Following the acquisition, the chief executive officer now owns 16,667 shares of the company’s stock, valued at $25,000.50. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 5.50% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: “OncoSec Medical (ONCS) Given a $6.00 Price Target at HC Wainwright” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/12/oncosec-medical-oncs-given-a-6-00-price-target-by-hc-wainwright-analysts.html.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.